share_log

Zentek to Present at the Sidoti & Company Virtual Small Cap Conference

Zentek to Present at the Sidoti & Company Virtual Small Cap Conference

Zentek將出席Sidoti&Company虛擬小盤股大會
Accesswire ·  2022/01/17 21:35

GUELPH, ON / ACCESSWIRE / January 17, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN) and (OTC:ZENYF), an IP development and commercialization company focused on next-gen healthcare solutions, announces that Chief Executive Officer Greg Fenton will present at the Sidoti & Company Virtual Small Cap Conference being held from January 19 - 20, 2022.

Guelph,on/ACCESSWIRE/2022年1月17日/Zentek Ltd. ("禪宗“或”公司)(多倫多證券交易所股票代碼:ZEN)和專注於下一代醫療解決方案的知識產權開發和商業化公司(場外交易代碼:ZENYF)宣佈,首席執行官格雷格·芬頓將出席2022年1月19日至20日舉行的Sidoti&Company虛擬小型股大會。

Mr. Fenton will deliver his corporate presentation on Thursday, January 20, 2022, at 9:15 AM ET, and can be accessed live:

芬頓先生將於2022年1月20日(星期四)美國東部時間上午9:15發表公司演示文稿,可現場收看:

Mr. Fenton will also be available for one-on-one meetings throughout the conference.

芬頓先生還將在整個會議期間參加一對一的會議。

About Zentek Ltd.

關於Zentek有限公司

Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

Zentek是一家納米技術公司,在預防、檢測和治療領域開發下一代醫療解決方案並將其商業化。Zentek目前專注於商業化禪宗Guard™,一種正在申請專利的塗層,被證明具有99%的抗菌活性,包括對新冠肺炎的抗菌活性,並有可能將類似的化合物用作治療傳染病的產品。該公司還有一項獨家協議,將成為一項新開發的基於適體的快速病原體檢測技術的全球商業化合作夥伴。

For further information:

有關更多信息,請訪問:

Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com

馬特·布拉澤(Matt Blazei)
電話:(212)655-0924
電子郵件:mattb@coreir.com

To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at .

欲瞭解更多有關Zentek Ltd.的信息,請訪問我們的網站:。本新聞稿的副本和與本公司有關的所有重要文件可在Zen的SEDAR簡介中獲得,網址為。

Forward-Looking Statements

前瞻性陳述

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

本新聞稿包含前瞻性陳述。由於前瞻性陳述涉及未來的事件和條件,因此它們本身就包含固有的風險和不確定因素。儘管Zentek認為在準備本新聞稿中的前瞻性信息時使用的假設和因素是合理的,但不應過度依賴這些信息,因為這些信息只適用於本新聞稿發佈之日,不能保證此類事件將在披露的時間框架內發生或根本不會發生。除法律要求外,Zentek沒有任何更新或修改任何前瞻性信息的意圖或義務,無論是由於新信息、未來事件還是其他原因。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

SOURCE: Zentek Ltd.

資料來源:Zentek Ltd.


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論